{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T23:57:05Z","timestamp":1769558225543,"version":"3.49.0"},"reference-count":13,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2004,5,14]],"date-time":"2004-05-14T00:00:00Z","timestamp":1084492800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Epilepsia"],"published-print":{"date-parts":[[2004,6]]},"abstract":"<jats:p><jats:bold>Summary:\u2003<\/jats:bold><jats:italic>Purpose:<\/jats:italic>Disabling myoclonus is the main symptom in long\u2010standing Unverricht\u2013Lundborg disease (ULD), and levetiracetam (LEV) appears to be an effective anticonvulsant with promising short\u2010term antimyoclonic properties.<\/jats:p><jats:p><jats:italic>Methods:<\/jats:italic>LEV was prescribed to 13 patients with ULD. We retrospectively analyzed the efficacy of LEV on seizure frequency and on myoclonus, by using a simplified myoclonus rating score, and compared the patients' status before LEV and at the last follow\u2010up. They were two women and 11 men, aged 14 to 52 years (mean, 36.5 years), with a disease duration of 4 to 40 years (mean, 24.3 years). LEV was given at 2,000 to 4,000 mg\/d for 0.5 to 26 months (mean, 13.8 months).<\/jats:p><jats:p><jats:italic>Results:<\/jats:italic>One patient stopped LEV within 2 weeks because of side effects and lack of efficacy. None of the other 12 patients reported side effects. The average myoclonus score significantly changed from 3.1 to 2.4 (p = 0.01), but only eight had a measurable improvement.<\/jats:p><jats:p><jats:italic>Conclusions:<\/jats:italic>The best effects were noted in the younger patients. In patients previously treated with high\u2010dose piracetam (PIR), discontinuation of PIR was not always well tolerated, and a combination of PIR at lower doses and LEV appeared to be a practical solution. LEV should probably be considered as a major treatment option early in the course of ULD.<\/jats:p>","DOI":"10.1111\/j.0013-9580.2004.56902.x","type":"journal-article","created":{"date-parts":[[2004,5,14]],"date-time":"2004-05-14T13:43:22Z","timestamp":1084542202000},"page":"678-681","source":"Crossref","is-referenced-by-count":90,"title":["Antimyoclonic Effect of Levetiracetam in 13 Patients with Unverricht\u2013Lundborg Disease: Clinical Observations"],"prefix":"10.1111","volume":"45","author":[{"given":"Adriana","family":"Magaudda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Gelisse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Genton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2004,5,14]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410280129"},{"key":"e_1_2_5_3_2","first-page":"407","volume-title":"Epileptic syndromes in infancy, childhood and adolescence","author":"Genton P"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1999.tb00895.x"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1086\/301798"},{"issue":"1","key":"e_1_2_5_6_2","first-page":"49","article-title":"Piracetam in the treatment of cortical myoclonus","volume":"32","author":"Genton P","year":"1999","journal-title":"Pharmacopsychiatry"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.64.3.344"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.58.5.781"},{"key":"e_1_2_5_9_2","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1684\/j.1950-6945.2000.tb00445.x","article-title":"Antimyoclonic effect of levetiracetam","volume":"2","author":"Genton P","year":"2000","journal-title":"Epileptic Disord"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000058755.38892.80"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-973530"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.40.9.1412"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.47.5.1264"},{"key":"e_1_2_5_14_2","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1684\/j.1950-6945.2000.tb00363.x","article-title":"Piracetam and levetiracetam: close structural similarities but different pharmacological profiles","volume":"2","author":"Genton P","year":"2000","journal-title":"Epileptic Disord"}],"container-title":["Epilepsia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.0013-9580.2004.56902.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.0013-9580.2004.56902.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T18:30:33Z","timestamp":1734373833000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.0013-9580.2004.56902.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,5,14]]},"references-count":13,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2004,6]]}},"alternative-id":["10.1111\/j.0013-9580.2004.56902.x"],"URL":"https:\/\/doi.org\/10.1111\/j.0013-9580.2004.56902.x","archive":["Portico"],"relation":{},"ISSN":["0013-9580","1528-1167"],"issn-type":[{"value":"0013-9580","type":"print"},{"value":"1528-1167","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,5,14]]}}}